The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity
To quantify the impact of Glucagon-like peptide1 receptor-agonists (GLP1-RAs) on asthma control, we analysed people with asthma and obesity, using the Optimum Patient Care Research Database (OPCRD). We identified 10,111 GLP1-RA exposed people and 50,555 unexposed controls. The exposed cohort had higher BMI and more uncontrolled asthma [risk domain asthma control (RDAC) and overall asthma control (OAC)]. The exposed cohort lost more weight and had improved asthma control for both RDAC (odds ratio 2.11 95% CI 1.90-2.36) and OAC (OR 2.10, 95%CI 1.81-2.45) scores. GLP1-RA drugs appear to improve asthma control for people with obesity.
Authors
- Derek Skinner (ORCID: https://orcid.org/0000-0002-7112-9317)
- Richard C. Hubbard
- John Townend (ORCID: https://orcid.org/0000-0002-5881-5806)
- Alan G. Kaplan (ORCID: https://orcid.org/0000-0001-8795-5528)
- David Price (ORCID: https://orcid.org/0000-0002-9728-9992)
- Victoria Carter (ORCID: https://orcid.org/0000-0002-0333-3308)
- Tan Tze Lee
- Heath Heatley
- Mariko Siyue Koh
Institutions
- Singapore General Hospital (SG)
- Observational & Pragmatic Research Institute (SG)
- National University Health System (SG)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1007/s12325-025-03175-x
- Citations
- 10
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 12.95
Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Teva Pharmaceutical Industries
- Purdue University
- Regeneron Pharmaceuticals
- Covis Pharma
- Moderna
- Singapore General Hospital
- Eisai
- Novo Nordisk
- Idorsia Pharmaceuticals
- Sanofi Genzyme
- Efficacy and Mechanism Evaluation Programme